Loading...
Market
Public perception shift of OpenAI's bio-science involvement by end of 2025?
2
Resolution / Starting Odds
Positive • 25%
Neutral • 25%
Negative • 25%
No Significant Change • 25%
Surveys or media analysis reports
Story
OpenAI's GPT-4b Micro Model Aims to Boost Longevity by Engineering Yamanaka Factors for Stem Cells
Jan 17, 2025, 07:11 PM
OpenAI, in collaboration with Retro Biosciences, has developed a new AI model named GPT-4b micro, aimed at enhancing longevity science through the engineering of proteins. This model focuses on re-engineering Yamanaka factors, proteins that can transform regular cells into stem cells, which are crucial for potential advancements in regenerative medicine and extending human lifespan. The project, which began about a year ago, was initiated after Retro Biosciences approached OpenAI. Sam Altman, CEO of OpenAI, has personally invested $180 million in Retro, which is working towards extending the human lifespan by 10 years. Preliminary results suggest that the AI model's suggestions have improved the effectiveness of the Yamanaka factors by more than 50 times, according to OpenAI. This development marks OpenAI's first foray into biological data and its first public claim of delivering unexpected scientific results, positioning it as a step towards artificial general intelligence (AGI).
View original story
Similar markets
Mixed views • 25%
No change • 25%
Worsened perception • 25%
Improved perception • 25%
Mostly Negative • 25%
Neutral • 25%
Mixed • 25%
Mostly Positive • 25%
Mixed opinions • 25%
Improved perception • 25%
Unchanged perception • 25%
Worsened perception • 25%
Improved reputation • 25%
Significant negative impact • 25%
Moderate negative impact • 25%
No significant impact • 25%
Somewhat Positive • 25%
Very Positive • 25%
Negative • 25%
Neutral • 25%
Mixed opinions • 25%
No change • 25%
Declined perception • 25%
Improved perception • 25%
New Partner • 25%
Existing Tech Company • 25%
No New Collaboration • 25%
Retro Biosciences • 25%
Organ regeneration • 25%
Other • 25%
Neural enhancement • 25%
Genetic modification • 25%
Copyright compliance • 25%
AI ethics • 25%
No significant changes • 25%
Transparency • 25%
Closer national security ties • 25%
No significant change • 25%
Supportive AI regulations • 25%
Increased AI investment • 25%
Decreased concern • 25%
Mixed opinions • 25%
Increased concern • 25%
No significant change • 25%